Interpace Diagnostics Group (NASDAQ:IDXG) issued its earnings results on Tuesday. The business services provider reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.04), Morningstar.com reports. The firm had revenue of $5.75 million during the quarter, compared to analysts’ expectations of $5.50 million. Interpace Diagnostics Group had a negative net margin of 71.14% and a negative return on equity of 34.58%.
Interpace Diagnostics Group stock traded down $0.26 during mid-day trading on Wednesday, hitting $1.20. The company had a trading volume of 36,322 shares, compared to its average volume of 243,353. Interpace Diagnostics Group has a 12-month low of $0.77 and a 12-month high of $1.78. The firm has a market cap of $41.75 million, a PE ratio of -1.47 and a beta of 2.26.
Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $172,000. JPMorgan Chase & Co. purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $194,000. Essex Investment Management Co. LLC purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $465,000. Finally, Perkins Capital Management Inc. purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $983,000. Institutional investors and hedge funds own 15.55% of the company’s stock.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.